Tibinyl p500

Tibinyl p500 is included in the drug subgroup of second-line anti-tuberculosis drugs.

In the case of prescribing therapy using this medication, it is necessary to take into account that monotherapy can provoke the rapid development of pronounced resistance against it in mycobacterium tuberculosis. In this regard, the medication is usually used in combination with other anti-tuberculosis substances. [1]

Indications Tibinyl p500

It is used for all types of tuberculosis (as part of a combination treatment).

Release form

The release of the drug element is made in tablets.

Pharmacodynamics

The medicine passes without complications into the foci of the location of the tuberculous lesion. The therapeutic effect is not weakened under the influence of the acidic environment of the caseous masses, which makes it possible to use the drug in the case of caseous lymphadenitis, as well as caseous-pneumonic infections and tuberculomas. [2]

Pharmacokinetics

Pyrazinamide is almost completely absorbed inside the gastrointestinal tract. After oral administration of 1 g of the substance, its plasma index is 45 μg / ml (after 2 hours) and 10 μg / ml (after 15 hours).

Tibinyl p500 undergoes hydrolysis with the formation of an active metabolic element - pyrazinic acid. After that, it is transformed into a metabolite that has no activity. [3]

The term drug half-life for healthy renal function is 9-10 hours. Pyrazinamide is 70% excreted through the kidneys. Excretion is realized over a period of 24 hours (most of it is in the form of metabolic components).

Dosing and administration

For persons over the age of 15 and adults, the medication is administered in portions of 20-35 mg / kg (for 1-3 uses, after a meal).

The medicine can be used in a dosage of 90 mg / kg once a week or in a portion of 2-2.5 g, 3 times a week. In addition, a dosage of 3-3.5 g can be used, 2 times a week, taking into account the patient's weight (with a weight below 50 kg, a portion is equal to 165-1500 mg, and with a weight of more than 50 kg - 2000 mg).

The size of the daily portion with a weight of less than 50 kg and in persons over 60 years of age is 1.5 g. A child can take a maximum of 1.5 g of the medication per day.

• Application for children

Not for use on persons under 15 years of age.

Use Tibinyl p500 during pregnancy

It is forbidden to prescribe medication during pregnancy or hepatitis B.

Contraindications

Among the contraindications:

• severe intolerance associated with a drug;
• hepatic pathology;
• gout.

Side effects Tibinyl p500

The main side symptoms:

• digestive problems: nausea, diarrhea, vomiting and hepatic disorder;
• signs of allergies: itching, epidermal rash and arthralgia;
• others: active form of gout or hyperuricemia. The appearance of photosensitization has been reported.

Interactions with other drugs

Pyrazinamide reduces the plasma levels of cyclosporine.

The drug increases the plasma level of uric acid and weakens the activity of anti-gout drugs (including sulfinpyrazone with allopurinol) when combined with them.

Storage conditions

Tibinyl p500 must be stored in a place away from small children and sunlight. Temperature is standard for medicinal substances.

Shelf life

Tibinyl p500 can be applied within a 3-year term from the date of implementation of the therapeutic element.

Analogs

Analogues of drugs are Paizin, Phenazid with Theriz, as well as Inbutol and Pira.